MedTrace Logo

Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

NCT03899324 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-07-23

No results posted yet for this study

Summary

This is multicentre, proof of concept, randomized, double-blind, parallel-group, placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in 2 groups receiving Bumetanide or placebo for 4 months:

* Group 1 (20 PD patients): bumetanide
* Group 2 (20 PD patients): placebo intake identically to group 1.

Conditions

  • Parkinson Disease

Interventions

DRUG

Bumetanide white, oblong, scored tablet

Bumetanide with a titration period

DRUG

Placebo white, oblong, scored tablet

placebo intake identically to group 1

Sponsors & Collaborators

  • B&A Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-26
Primary Completion
2020-09-30
Completion
2021-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899324 on ClinicalTrials.gov